Introduction
============

Cervical cancer is one of the most common gynecological tumors. More than 569,847 women are diagnosed with cervical cancer annually worldwide, resulting in over 311,365 deaths ([@B7]). Although the incidence of cervical cancer has been greatly reduced by the use of HPV vaccines and cervical cancer screening ([@B20]), cervical cancer is second in terms of morbidity among gynecological tumors in developing countries ([@B48]). Over 70% of cervical cancer cases diagnosed in developing countries are locally invasive or metastatic, contributing to the high mortality rate of cervical cancer. The 5-year OS rate of local cervical cancer can achieve approximately 75--85% through effective treatments such as surgery CCRT, etc. ([@B9]). Nevertheless, the 5-year OS of recurrent, persistent, metastatic cervical cancer is only approximately 15%. The poor prognosis is mainly due to limited therapeutic options ([@B22]). The majority of these patients can only be treated with palliative chemotherapy ([@B5]), in which platinum-based chemotherapies were the prior choice ([@B40]). In 2014, the GOG 240 trial indicated that when bevacizumab was added to the chemotherapy, the ORR was improved from 36 to 48% ([@B53]), and the OS could be prolonged from 13 to 17 months for recurrent, persistent, metastatic cervical cancer, thus laying the foundation for the first-line choice of combining bevacizumab with chemotherapy for this population ([@B54]). However, for those who progress during the first-line treatment, the lack of effective second-line treatment remains to be the main reason for the high mortality rate ([@B39]). Currently, immune checkpoint inhibitors ([@B50]), especially PD-1/PD-L1 inhibitors ([@B12]), have achieved favorable efficacy in treating multiple solid tumors ([@B19]), including cervical cancer ([@B4]). Accumulating evidence has demonstrated that PD-1/PD-L1 inhibitors may be a promising approach for cervical cancer treatment.

Immune Checkpoint Inhibitors
============================

Numerous immunomodulatory therapies are being investigated in clinical trials with diverse potential targets, including PD-1/PD-L1, CTLA-4, Tim-3, ICOS, 4-1BB, and OX-40. Among these novel targets, ICOS ([@B1]), 4-1BB ([@B11]), and OX-40 ([@B44]) are costimulatory receptors, while PD-1/PD-L1 ([@B46]), CTLA-4 ([@B31]), and Tim-3 ([@B21]) are negative immune regulators of T cells. Currently, only CTLA-4 inhibitors ([@B24]) and PD-1/PD-L1 inhibitors ([@B2]) have been approved by the FDA. CTLA-4 integrates with the costimulatory molecules CD80 (B7-1) and CD86 (B7-2) that express on the surfaces of APCs ([@B16]), while PD-L1 is expressed on a wide variety of cell types, including tumor-associated fibroblasts, tumor cells, APCs, etc. ([@B6]). As a result, CTLA-4 inhibits T cell activation within secondary lymphoid organs ([@B28]), but PD-1/PD-L1 chiefly regulates T cell function within peripheral tissues and the tumor microenvironment ([@B42]). Therefore, PD-1/PD-L1 signaling is more specific to tumor than CTLA-4 signaling, and inhibitors of PD-1/PD-L1 may cause less damage to healthy tissue ([@B6]; [@B39]) ([Figure 1](#F1){ref-type="fig"}).
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Based on the above mechanism, ipilimumab (monoclonal anti-CTLA-4), the first immune checkpoint inhibitor, approved for melanoma, had little clinical benefit until the emergence of pembrolizumab, and the combination of the two drugs further improved treatment efficacy in malignant melanoma ([@B55]). To date, another mAb for CTLA-4, tremelimumab, has not been approved for the treatment in any type of cancer. However, mAbs targeting PD-1 \[pembrolizumab ([@B43]), nivolumab ([@B36]), and cemiplimab ([@B51])\] and PD-L1 \[atezolizumab ([@B26]), durvalumab ([@B52]), and avelumab ([@B30])\] have presented clinical advantages in malignant melanoma, advanced NSCLC, urothelial cancer ([@B59]) and other tumors ([@B32]) ([Table 1](#T1){ref-type="table"}). In addition, extensive research has been carried out on gynecological tumors, such as ovarian cancer ([@B34]) and breast cancer ([@B27]), and clinical researches on cervical cancer are ongoing. At present, some initial results have been achieved.

###### 

The characteristics of the clinical application of monoclonal antibodies (mAbs) of immune checkpoint inhibitors in cervical cancer.

  Target   Drug (trade name)          Antibody type   Formerly name            Manufacturer   Time to market (FDA)       Indications
  -------- -------------------------- --------------- ------------------------ -------------- -------------------------- ---------------------------------------------------------------------------------------------
  CTLA-4   Ipilumumab (Yervoy)        IgG1            --                       BMS            March, 2011                Melanoma, colorectal cancer, renal cell carcinoma
           Tremelimumab               IgG2            Ticilimumb, CP-675,206   Pfizer         --                         Undergoing human trials has not attained approval for any
  PD-1     Pembrolizumab (Keytruda)   IgG4            MK-3475 Lambrolizumab    MSD            September, 2014            Advanced melanoma, non-small cell lung cancer, Hodgkin's lymphoma, and head and neck SCC^1^
           Nivolumab (Opdivo)         IgG4            BMS-9365580 NO-4538      BMS            December, 2014             Metastatic melanoma, squamous non-small cell lung cancer, renal cell carcinoma
           Cemiplimab (REGN2810)      IgG4            --                       Sanofi         September, 2018 (EMA^2^)   squamous cell skin cancer (EMPOWER-CSCC 1)
  PD-L1    Durvalumab (Imfiniz)       IgGlK           --                       AstraZeneca    May, 2017                  Bladder cancer, NSCLC^3^
           Atezolizumab (Tecentriq)   IgGl            --                       Roche          April, 2016                Lung cancer, bladder cancer, advanced triple negative breast cancer
                                                                                                                         

1

SCC, squamous cell cancers;

2

EMA, European Medicines Agency;

3

NSCLC, non-small cell lung cancer.

Theoretical Basis for PD-1/PD-L1 Inhibitors in Cervical Cancer
==============================================================

The PD-1/PD-L1 axis is one of the most well-known immune-checkpoint pathways with a mechanism of immune evasion for cancer cells and thus inhibiting the immune response in various kinds of solid tumors, including cervical cancer [@B8]. In brief, PD-L1 expresses on the surface of cervical tumor cells, APCs and TILs, while the PD-1-positive cells were mostly identified as T cells in the stroma of cervical tumors. For the expression of PD-1 in the tumor stroma of cervical cancer, [@B37] reported that 60.82% (59/97) of the patients exhibited PD-1 expression, while another study showed PD-1 expression in 46.97% (31/66) of the patients ([@B15]).

To date, numerous studies have investigated the expression of PD-L1 in cervical cancer ([@B57]; [@B10]). The expression of PD-L1 has been reported in 34.4--96% of cervical carcinoma tissues, while expression of PD-L1 in histologically normal cervical tissues was rarely found ([@B14]). Opal [@B47] showed that PD-L1 expression was positive in 32 of 93 (34.4%) cervical carcinoma samples, subcategorically in 28 of 74 (37.8%) SCCs, 2 of 7 (28.6%) adenosquamous carcinomas, and 2 of 12 (16.7%) endocervical adenocarcinomas. In another study, PD-L1 expression was found in 96% of the samples ([@B14]). Specifically, for cervical SCC, PD-L1 expression was found in 80% (56/70) cases ([@B38]). In the TCGA database for cervical SCCs, the amplification or gain of PD-L1 was found in 28 of 129 (22%) cases ([@B13]). In addition, PD-L1 can also be expressed on TILs, which plays a role in antitumor response inhibition. A study found that for cervical SCCs samples, the expression rates of PD-L1 on cancer cells and TILs were 59.1 and 47.0%, respectively ([@B15]). Collectively, these data suggest that both PD-L1 and PD-1 are widely expressed in cervical cancer tumor cells and stroma, providing potential therapeutic targets for PD-1/PD-L1 inhibitors.

Notoriously, persistent HPV infection is involved in the pathogenesis of cervical cancer and is related to its prognosis. Several teams have interrogated whether HPV infection could affect PD-L1 expression in cervical cancer and found that HPV positivity was positively correlated with increased PD-L1 expression ([@B38]; [@B33]).

Considerable effort has been made to dissect the underlying mechanism of the association between HPV status and PD-L1 expression in HPV-related solid tumors, mainly HNSCC and cervical cancer. In HPV-HNSCCs, membranous expression of PD-L1 and significant increased levels of mRNA of IFN-γ were found in the tonsillar crypts, As tonsillar crypts witnesses the initial HPV infection, and IFN-γ induces PD-L1 expression, this evidence might support the role of the PD-1/PD-L1 interaction in creating an "immune-privileged" site for initial viral infection and subsequent adaptive immune resistance ([@B17]). In another study, DNA methylation of PD-L1 was inversely correlated with PD-L1 mRNA expression (*p* ≤ 0.002) and was further significantly associated with HPV infection in the TCGA cohort, indicating that DNA methylation of PD-L1 is associated with transcriptional silencing and HPV infection in HNSCCs ([@B3]). In cervical cancer, [@B45] indicated that HPV-induced somatic mutations and a multitude of neoantigens, which played a crucial role in the inhibitory tumor microenvironment and could lead to notable alterations among checkpoint-related genes such as CTLA-4, PD-1, and PD-L1. Specifically, PD-L1 showed a positive correlation with ENO1, PRDM1, OVOL1, and MNT, all of which are related master regulators of HPV16 E6 and E7 ([@B45]). Of note, a single-arm, phase II study investigated durvalumab in patients with recurrent/metastatic HNSCCs (*n* = 112) and found that HPV-positive patients had a higher response rate and better survival than that of the HPV-negative patients ([@B58]). Nevertheless, for cervical cancer, the association of HPV status and the efficacy of PD-1/PD-L1 inhibitors is not yet certain due to the paucity of available data.

Several studies have probed the role of PD-L1 expression in the prognosis and therapeutic efficacy of cervical cancer. These results separately proved that an increase in PD-L1 expression was positively associated with tumor metastasis ([@B56]), tumor progression ([@B26]) and poor prognosis in cervical cancer ([@B23]). In this regard, the negative relationship between HPV infection and the clinical outcomes of cervical cancer may be partially attributed to the PD-L1 expression induced by HPV infection ([@B56]). For patients with locally advanced cervical adenocarcinoma and adenosquamous carcinoma treated with CRT, the underexpression of PD-L1 was a prognostic factor for tumor relapse (*p* = 0.041), indicating that PD-L1 expression might be a novel biomarker for CRT outcome ([@B29]).

Clinical Research Outcomes of PD-1/PD-L1 Inhibitors in Cervical Cancer
======================================================================

Since 2015, multiple clinical trials have been conducted to explore the application of PD-1/PD-L1 antibodies in cervical cancer. To date, four studies have yielded preliminary results ([Table 2](#T2){ref-type="table"}). Keynote 028 (a phase Ib study) and Keynote 158 (a phase II study) evaluated pembrolizumab at the dose of 10 mg/kg and 200 mg/kg, respectively, in recurrent, metastatic cervical cancer. In Keynote 028 ([@B18]), 24 patients were enrolled, and the overall response rate (RECIST v1.1) was 17% (95% CI: 5 to 37%). In terms of toxicity, 5 patients experienced grade 3 AEs (NCI-CTCAE 3.0), while no grade 4 AEs was observed. In Keynote 158 ([@B49]), 98 patients with recurrent or metastatic cervical cancer were enrolled. With a median follow-up time of 11.7 months, the ORR in 77 patients was 14.3% (95% CI: 7.4 to 24.1%), including 2.6% of the patients with CRs and 11.7% of patients with PRs, whereas no response was observed in patients without PD-L1 expression in tumor cells. The most frequent serious adverse reactions included anemia (7%), fistula (4.1%), hemorrhage (4.1%), and infection (4.1%). Based on Keynote 158, the FDA approved pembrolizumab on June 12, 2018, for advanced cervical cancer with disease progression during or after chemotherapy^[1](#fn01){ref-type="fn"}^. Checkmate 358 ([@B25]) (phases I--II studies) adopted nivolumab (200 mg/kg q2w) for the treatment of recurrent, metastatic cervical cancer and resulted in an ORR of 26.3%. The disease control rate was 70.8%. The related grades 3--4 toxic effects included hyponatremia, syncope, diarrhea, and hepatocellular injury. From these three studies, pembrolizumab and nivolumab showed promising antitumor effects and were well-tolerated in patients with recurrent or metastatic cervical cancer. However, due to a limited follow-up time, PFS and OS were not reported. Additionally, the REGN2810 study ([@B41]), a phase I multicenter study, assessed REGN2810 (a PD-1 mAb) as a monotherapy and in combination with hfRT, in combination with cyclophosphamide (CTX) or with CTX + hfRT in patients with advanced solid tumors, including cervical cancer. This study adopted a dose escalation design, and as of February 2016, no dose-limiting toxicity (DLT) was observed. The most common treatment-related AEs were fatigue (*n* = 14, 24.1%), arthralgia (*n* = 7, 12.1%), and nausea (*n* = 6, 10.3%). Additionally, 4 patients experienced grade ≥ 3 AEs. For 9/22 (40.9%) patients who received REGN2810 + hfRT and 2/21 (9.5%) patients who received REGN2810 monotherapy, they were determined to have partial/uPRs, suggesting that the treatment response was augmented by the addition of hfRT.

###### 

Clinical research outcomes on PD-1/PD-L1 inhibitors in cervical cancer.

  Study           Author   Study population (n)                                                                 Phase   Treatment arm(s)              Principal results                                                                                                   Toxicity                                                                              Significance
  --------------- -------- ------------------------------------------------------------------------------------ ------- ----------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  REGN2810        [@B41]   Advanced solid tumors                                                                I       Cemiplimab                    62.8% patients had disease control                                                                                  No dose-limiting toxicities                                                           Higher response rate when combined with radiation suggesting abscopal responses
  Keynote 028     [@B18]   Recurrent cervical cancer with PD-L1 positive tumors (24)                            Ib      Pembrolizumab 10 mg/kg q2w    ORR^1^ 17% (95% CI: 5--37%)                                                                                         Grade=3 AE^2^ including rash and proteinuria                                          Well-tolerated and active in cervical cancer
  Keynote 158     [@B49]   Recurrent cervical cancer with progression or intolerance to standard therapy (82)   II      Pembrolizumab 200 mg/kg q2w   Preliminary results: ORR^1^ 17% (95% CI: 8--31%); patients with \>27 weeks of follow up, ORR 27% (95% CI: 8--55%)   Grades 3--4 AE^2^ included AST/ALT^3^ elevation and pyrexia                           Demonstrates activity in cervical cancer and increasing response with a longer duration of follow-up
  Checkmate 358   [@B25]   Recurrent or metastatic HPV^4^-related cancers (19)                                  I--II   Nivolumab 240 mg q2w          Preliminary results: ORR^1^ 26% (95% CI: 9.1--51.2%) in cervical cancer patients                                    Grade 3--4 AE^2^ included hyponatremia, syncope, diarrhea and hepatocellular injury   Durable responses demonstrated in cervical cancer patients, with at least 6 months duration
                                                                                                                                                                                                                                                                                                                                                                

1

ORR, objective response rate;

2

AE, adverse event;

3

AST/ALT, aspartate transaminase/alanine transaminase;

4

HPV, human papillomavirus.

Ongoing Clinical Research on PD-1/PD-L1 in Cervical Cancer
==========================================================

As of September 2018, 11 clinical trials have been conducted, mainly in patients with persistent, recurrent, or metastatic cervical cancer, with only three studies on patients with locally advanced cervical cancer. Twenty to thirty cases were intended to be included in the majority of these studies, while there were only three studies (Keynote 826, GOG 3016/ENGOT-cx9, and NCT03556839) in which more than 200 cases were intended to be included. Except for the two studies (IMMUVIX, GHR002) aimed at exploring the immune status of PD-1/PD-L1 in patients with locally advanced cervical cancer, the remaining 12 studies all looked into the applicability of PD-1/PD-L1 inhibitors in cervical cancer. Of these 12 studies, there are 2 studies on nivolumab, 2 on pembrolizumab, 4 on durvalumab, 2 on atezolizumab, 1 on cemiplimab (REGN2810) and 1 on AGEN2034. For PD-1 inhibitors, the difference between the 2 studies on nivolumab is the study population. NRG-GYO-02 was conducted in patients with persistent, recurrent, or metastatic cervical cancer, while the NiCOL study enrolled more patients with locally advanced cervical cancer. The main difference between the two studies on pembrolizumab is that KEYNOTE-826 adopted pembrolizumab in combination with chemotherapy versus placebo, while PAPAYA mainly adopted pembrolizumab in combination with platinum and radiotherapy. The GOG 3016/ENGOT-cx9 (EMPOWER-Cervical) study is an important phase III clinical study to advance the clinical application of cemiplimab (REGN2810) in advanced cervical cancer. NCT03104699 is a phase I/II clinical study on AGEN2034, another PD-1 inhibitor, in advanced solid tumors that includes 75 cases of cervical cancer. In terms of treatment combinations, tremelimumab (a fully human mAb against CTLA-4), Vigil vaccine for cervical cancer, bevacizumab, and chemotherapy were paired with PD-1/PD-L1 inhibitors throughout these studies ([Table 3](#T3){ref-type="table"}).

###### 

Ongoing clinical research on PD-1/PD-L1 in cervical cancer.

  Clinical trial code   Study                                                                                                                                                                                                                           Study population (n)                                                Phase             Treatment arm(s)                                 Primary outcome measures                                          Secondary outcome measures
  --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ----------------- ------------------------------------------------ ----------------------------------------------------------------- -----------------------------------------------------------------------------------------
  NCT02257528           Nivolumab in Treating Patients with Persistent, Recurrent, or Metastatic Cervical Cancer (NRG-GYO-02)                                                                                                                           Recurrent or metastatic cervical cancer (25)                        II                Nivolumab                                        ORR^1^ \[5 y\]; AE^2^ \[100 d\]                                   PFS^3^ \[5 y\], OS^4^ \[5 y\]
  NCT03298893           Nivolumab in Association with Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)                                                                         Locally advanced cervical cancer (21)                               III               Nivolumab                                        DLT^5^ \[11 w\]                                                   ORR^1^ \[2 m\], PFS^3^ \[2 y\], DFS^6^ \[2 y\], SAE^7^ \[100 d\], AE^2^ \[100 d\], etc.
  NCT03257267           Study of REGN2810 in Adults with Cervical Cancer (GOG 3016/ENGOT-cx9) (EMPOWER-Cervical)                                                                                                                                        Recurrent or metastatic platinum-refractory cervical cancer (436)   III               Cemiplimab (REGN2810)                            OS^4^ \[32 m\]                                                    PFS^3^ \[32 m\], ORR^1^ \[32 m\], DOR^8^ \[32 m\], Quality of life (QOL) \[100 w\]
  NCT03104699           Phase 1/2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer                                                                                                                                                              Advanced cervical cancer (75)                                       I--II             AGEN2034                                         DLTs^5^ \[3 w\], MTD^9^ \[1 y\], BOR^10^ \[1 y\]                  Cmax^11^ \[1 y\], AUC^12^ \[1 y\], PFS^3^ \[1 y\], DOR^8^ \[1 y\], OS^4^ \[1 y\]
  NCT03518606           Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients with Advanced Solid Tumors (MOVIE)                                                                                                             Advanced solid tumors (150) including cervical cancer               I--II             Durvalumab+Tremelimumab+metronomic Vinorelbine   Phase I: MTD^9^ and RP2D^13^ \[9 m\] Phase II: CBR^14^ \[24 m\]   None
  NCT03556839           Platinum Chemotherapy Plus Paclitaxel with Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix                                                                                                                   Carcinoma of the cervix, stage IVB (404)                            III               Atezolizumab                                     OS^4^ \[48 m\]                                                    PFS^3^ \[48 m\], ORR^1^ \[48 m\], DOR^8^ \[48 m\], AE^2^ \[48 m\], etc.
  NCT01975831           A Phase 1 Study to Evaluate MEDI4736 in Combination with Tremelimumab                                                                                                                                                           Solid tumors (106) including cervical cancer                        I                 MEDI4736 (Durvalumab)+Trem elimumab              AE^2^ \[1 y\]                                                     AUC^12^, Cmax^11^ \[15 m\], PFS^3^ \[15 m\], OS^4^ \[15 m\], etc.
  NCT02914470           Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers (PROLOG)                                                                                                                                                        Solid tumors (12) including cervical cancer                         I                 Durvalumab and Vigil                             Toxicity \[30 d\]                                                 ORR^1^ \[120 m\]
  NCT02725489           Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers                                                                                                                                                                 Solid tumors (15) including cervical cancer                         II                Vigil+durvalumab                                 AEs^2^ \[90 d\]                                                   ORR^1^ \[12 m\], Disease status \[12 m\], IFNγ-ELISPOT conversion rate \[12 w\]
  NCT02921269           Atezolizumab and Bevacizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical Cancer                                                                                                                     Recurrent, persistent, or metastatic cervical cancer (22)           II                Atezolizumab+Bevac izumab                        ORR^1^ \[2 y\]                                                    PFS^3^ \[2 y\], OS^4^ \[2 y\] AE^2^ \[30 d\], PD-L1, etc.
  NCT03635567           Efficacy and Safety Study of First-line Treatment with Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women with Persistent, Recurrent, or Metastati Cervical Cancer (MK-3475-826/KEYNOTE-826)   Cervical cancer (600) c                                             I--II             Pembrolizumab                                    PFS^3^ \[2y\] OS^4^ \[2 y\]                                       ORR^1^ \[2 y\], DOR^8^ \[2 y\], etc.
  NCT03144466           A Study of Pembrolizumab And Platinum with Radiotherapy in Cervix Cancer (PAPAYA)                                                                                                                                               Cervical cancer (26)                                                I                 Pembrolizum                                      MTD^9^ \[2 y\] ab Efficacy \[2 y\]                                OS^4^ \[2 y\], PFS^3^ \[2 y\], etc.
  NCT03255252           Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX)                                                                                                      Cervical cancer (100)                                               II                Cisplatin                                        Expression of CD8+CD39+PD1+                                       Effect on 1-year DFS^6^ of other putative biomarkers (CD73, CD39, PD1 and Tim3)
  NCT03559803           A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer(GHR002)                                                                                                                                     Cervical cancer(50)                                                 Not appli cable   Cisplatin                                        PD-L1 \[3w, 2 m\]                                                 PD1+CD4+T \[3w, 2 m\], PD1+CD8+T \[3w, 2 m\], TCR\[3w, 2 m\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

1

ORR, objective response rate;

2

AE, adverse event;

3

PFS, progression-free survival;

4

OS, overall survival rate;

5

DLT, dose limiting toxicity;

6

DFS, disease-free survival;

7

SAE, serious adverse event;

8

DOR, duration of response;

9

MTD, maximum tolerated dose;

10

BOR, best overall response;

11

Cmax, maximum plasma concentration;

12

AUC, area under curve;

13

RP2D, phase II recommended dose;

14

CBR, clinical benefit response.

Conclusion
==========

Although there are a few studies suggesting the potential feasibility of PD-1/PD-L1 inhibitors for the treatment of cervical cancer, a consideration should be made for the clinical application of PD-1/PD-L1 inhibitors. The inadequate number of cases included and the insufficient follow-up time are the main defects of all the studies, leading to the unavailability of data regarding OS, PFS, AEs, drug resistance and the treatment mechanism as well. These data are very pivotal not only for obtaining a more convincing result, but also for guiding physicians to select the appropriate patients for PD-1/PD-L1 inhibitors.

Currently, most of these studies, including ongoing studies, are mostly limited to recurrent, persistent, metastatic cervical cancer, which accounts for only a minor portion of patients with cervical cancer. There are several future directions that can be given more attention. First, the latest evidence suggests a clinical benefit of PD-1/PD-L1 inhibitors as neoadjuvant therapy in lung cancer ([@B35]). For patients with early-stage cervical cancer, studies in a small sample size can be conducted to investigate PD-1/PD-L1 inhibitors with attempted surgical treatment or to prevent post-operative recurrence. Second, for patients with locally advanced cervical cancer who are not sensitive to CCRT or who relapse in the short term after initial treatment, PD-1/PD-L1 inhibitors may be a useful treatment, and we are looking forward to the research targeting this population. Third, for locally advanced cervical cancer patients, whether PD-1/PD-L1 inhibitors can achieve better therapeutic efficacy in tumors with higher PD-L1 expression before CCRT begins will provide a better understanding of the effects of these inhibitors. Finally, since PD-L1 expression is correlated with HPV status, more studies are warranted to provide further insights into the association of HPV status and the efficacy of PD-1/PD-L1 inhibitors in patients with cervical cancer. Combining the level of HPV DNA with the expression of PD-L1 may also provide a novel predictive biomarker of the efficacy of PD-1/PD-L1 inhibitors and the prognosis of patients with cervical cancer.
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